The stock of Hims & Hers Health Inc. (NYSE:HIMS) decreased by -$0.1 on Tuesday to finish at $6.24, down -1.58 percent. The last five days have seen an average of 2,708,420 shares of common stock traded. 23 times new highs were reached in the current year, with a fall of -$0.17. The average number of shares traded over the last 20 days was 2,109,045, while the average volume over the last 50 days totaled 3,020,500.
HIMS stock dropped -8.37% since last month. On 09/19/23, the company’s shares reached a one-month low of $6.17. The stock touched a high of $12.34 on 05/08/23, after rallying from a low of $4.01 in 52 weeks. The price of HIMS stock has declined by -2.65% or -$0.17 this year, reaching a new high 23 times. Still, the stock price is down -49.43% from the 52-week high.
Insider Transactions
HIMS stock investors should be aware that Hims & Hers Health Inc. (HIMS) stock had its last reported insider trading activity 14 days ago on Sep 06. On Sep 06, Chief Operating Officer Baird Melissa sold 9,133 shares at $6.87 each. This transaction resulted in the insider making $62,729. On Sep 05, Baird Melissa sold 9,133 shares at a price of US$6.80. After the transaction, the insider now owns 408,485 shares. Chief Operating Officer Baird Melissa had earlier sold 9,133 shares on Sep 01 for $6.87 a share. The transaction was completed for $62,740.
Valuation Metrics
Beta for the stock is 0.53. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.85, the price-to-book (PB) ratio of 4.05, and the price-to-cash flow ratio of 112.36.
Financial Health
For the three months ended June 29, Hims & Hers Health Inc.’s quick ratio was 3.20, while its current ratio was 3.50, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 80.30% percent. Hims & Hers Health Inc.’s EBITDA margin for the year ended June 29 was -11.58%, whereas its operating margin stood at -7.30% for the same period. Based on annual data, it had gross profit of $408.72 million and revenue of $526.92 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HIMS’s return on assets (ROA) during the last 12 months has been -12.40%. There was a -22.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -15.00%.
Earnings Surprise
According to Hims & Hers Health Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $207.16 million, while revenues rose by 45.18% to $190.77 million. It was predicted that Hims & Hers Health Inc.’s quarterly earnings would be -$0.03, but it ended up being -$0.05. EBITDA was -$8.34 million for the quarter. At the end of Hims & Hers Health Inc.’s most recent quarter ended June 29, its liabilities totaled 69.81 million, while its total debt was $5.09 million. Equity owned by shareholders amounts to $211.02 million.
Technical Picture
Here’s a quick look at Hims & Hers Health Inc.’s (HIMS) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 23.86%, suggesting the stock is oversold, with a 16.26% historical volatility rate.
The stochastic %K and %D were 13.77% and 13.51% respectively, while the average true range (ATR) was 0.25. Based on the 14-day stochastic reading of 7.61%, the RSI (14) reading is 27.94%. On the 9-day MACD Oscillator, the stock is at -0.13, and the 14-day reading is at -0.28.
Analyst Ratings
In its analyst report released on July 28, 2023, TD Cowen began covering Hims & Hers Health Inc. (NYSE: HIMS). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Hims & Hers Health Inc. (HIMS) an Overweight rating. HIMS is a stock that is recommended for selling by 0 brokerage firms, while 4 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is HIMS’s price target for the next 12 months?
The current consensus forecast for the stock is between $8.00 and $18.00, with a median target price of $11.00. In analyzing these forecasts, the average price target given by analysts for Hims & Hers Health Inc. (HIMS) is $12.11.
